



GI Dynamics, Inc. - ASX Announcement

GI Dynamics to Present at the Deutsche Bank 39th Annual Health Care Conference

LEXINGTON, Massachusetts & SYDNEY, Australia – 1 May 2014 – [GI Dynamics, Inc.](#) (ASX: GID) a company developing innovative treatments for type 2 diabetes and obesity, announced that Stuart A. Randle, president and chief executive officer, is scheduled to present at the Deutsche Bank 39th Annual Health Care Conference in Boston.

Mr. Randle will give a presentation and company overview on Thursday, May 8, 2014, at 2:50 p.m. ET. A live audio webcast of this presentation can be accessed by visiting <http://investor.gidynamics.com>. A replay will be available on the company's website for two weeks following the live presentation.

In addition, Mr. Randle will participate in a panel titled "Innovations in Endoscopic Surgery" to be held Thursday, May 8 from 12:00 – 12:45 p.m. ET.

About GI Dynamics

GI Dynamics, Inc. (ASX: GID) is the developer of EndoBarrier[®], the first endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S. EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States. GI Dynamics is conducting a pivotal clinical trial of EndoBarrier in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit www.gidynamics.com.

Investor Enquiries:

United States
Robert Crane, Chief Financial Officer
+1 (781) 357-3250

Australia
David Allen or John Granger, Hawkesbury Partners
Pty Limited
+61 2 9325 9046

Media Enquiries:

United States/Europe:
Dan Budwick, Pure Communications Inc.
+1 (973) 271-6085

Australia
Angela Ceberano, Flourish PR
+61 3 9092 8445